Verkkogrifols is accelerating adoption of xembify® as part of its broader immunoglobulin business strategy focused on treating immunodeficiency disorders,.
Verkkorare diseases remain a formidable public health challenge.
The key to unlocking breakthroughs in diagnosis and treatment is fostering dynamic.
$7. 5m allocated to.